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Introduction. We investigated the association of diabetic retinopathy and neuropathy with increased risk of recurrent
cardiovascular (CV) events in 6068 patients with type 2 diabetes mellitus (T2DM) and recent acute coronary syndrome (ACS)
enrolled in the Evaluation of Lixisenatide in Acute Coronary Syndrome (ELIXA). Methods. History of retinopathy and
neuropathy as well as duration of T2DM were self-reported at screening. Proportional hazards regression models were used to
assess relationships between retinopathy, neuropathy, and recurrent CV events. Results. At screening, retinopathy and
neuropathy were reported in 10.7% and 17.5% of patients, respectively, while 5.7% reported both. When adjusted for
randomized treatment only, both retinopathy and neuropathy were associated with a primary composite outcome (CV death,
nonfatal MI, stroke, or hospitalization for unstable angina) (retinopathy: HR 1.44, 95% CI 1.19–1.75; neuropathy: HR 1.33, 95%
CI 1.12–1.57), CV composite (CV death, nonfatal MI, stroke, hospitalization for heart failure (HF)) (retinopathy: HR 1.57, 95%
CI 1.31–1.88; neuropathy: HR 1.38, 95% CI 1.19–1.62), myocardial infarction (retinopathy: HR 1.38, 95% CI 1.08–1.76;
neuropathy: HR 1.26, 95% CI 1.02–1.54), HF hospitalization (retinopathy: HR 2.03, 95% CI 1.48–2.78; neuropathy: HR 1.71,
95% CI 1.30–2.27), and all-cause mortality (retinopathy: HR 1.65, 95% CI 1.28–2.12; neuropathy: HR 1.43, 95% CI 1.14–1.78).
When included in the same model, and adjusted for T2DM duration, there were no independent associations of either with CV
outcomes, while T2DM duration remained strongly associated with all outcomes. Addition of demographic characteristics and
CV risk factors did not further alter these relationships. Conclusions. In patients with T2DM and recent ACS, a history of
retinopathy and/or neuropathy and longer T2DM duration could be considered clinical markers for high risk of recurrent CV
events. This trial is registered with the ELIXA (Evaluation of Lixisenatide in Acute Coronary Syndrome), ClinicalTrials.gov
registration number NCT01147250.
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1. Introduction
Cardiovascular (CV) risk in type 2 diabetes mellitus (T2DM)
was associated with disease duration and severity of hyper-
glycemia in many studies [1–3]. In the Framingham Heart
Study, duration of T2DM signiﬁcantly and positively related
to the risk of coronary heart disease mortality, but not mor-
bidity, or CV disease (CVD) morbidity or mortality [2].
The Action in Diabetes and Vascular Disease: Preterax and
Diamicron Modiﬁed Release Controlled Evaluation
(ADVANCE) trial, on the contrary, showed that T2DM
duration was independently associated with the risk of
macrovascular complications and death [3]. In a meta-
analysis of ﬁve trials, intensive glycemic control led to a
reduction of nonfatal myocardial infarction (MI) incidence
by one-sixth, with no signiﬁcant eﬀect on the incidence of
nonfatal stroke, and both CV or all-cause mortality [4].
Additionally, duration of T2DM and severity of hyper-
glycemia are strong and consistent risk factors for the
development and progression of microvascular diabetic
complications—retinopathy (DR), neuropathy (DN), and
nephropathy [5–8]. For example, in the very large and
diverse T2DM population in ADVANCE, T2DM duration
was independently associated with the risk of DR and
nephropathy [3]. In the Maastricht Study, a T2DM-enriched
population-based cohort study prediabetes, T2DM, andmea-
sures of hyperglycemia were independently associated with
DR and DN [9]. Improved metabolic control was associated
with 25% risk reduction ofmicrovascular composite endpoint
in the United Kingdom Prospective Diabetes Study (UKPDS)
[10]. Similar eﬀect has been shown for individual complica-
tions, DR [5, 11], DN [6, 11], and nephropathy [7, 11, 12].
The association of diabetic nephropathy and increased
risk of CVD has been revealed in multiple patient cohorts.
Data from United States community-based study demon-
strated that individuals with diabetic nephropathy were at
four- and threefold higher risk for CV death and all-cause
death, respectively, compared to those without [13]. In the
ADVANCE study, both albuminuria and reduced estimated
glomerular ﬁltration rate (eGFR) were independently and
continuously associated with the risk for CV and kidney out-
comes in T2DM patients [14]. Similarly, among patients with
type 1 diabetes followed for over 30 years, the development of
diabetic nephropathy was associated with higher risks of
CVD and renal events. However, this eﬀect was almost
entirely eliminated by adjustment for updated mean HbA1c
which led to the conclusion that glycemic exposure correlates
very strongly with CVD and mortality, and that this is partly
mediated by hyperglycemia-induced renal disease [15].
Steno-2 study, including T2DM patients with microalbumi-
nuria, showed that long-term intensiﬁed therapy reduced
the risk of CV events, as well as diabetic nephropathy, DR,
and DN [16]. Also, the risk of microalbuminuria has been
shown to increase with T2DM duration [17].
Potential associations, of DR and DN with CV outcomes,
whether causal or only predictive, have received less atten-
tion. We therefore investigated the association of DR and
DN with increased risk of recurrent CV events, in patients
with a recent acute coronary syndrome (ACS).
2. Materials and Methods
2.1. Study Design and Patients. The ELIXA (Evaluation of
Lixisenatide in Acute Coronary Syndrome) was a random-
ized, double-blind, placebo-controlled trial designed to
assess the eﬀects of lixisenatide added to current T2DM
therapy on CV morbidity and mortality in 6068 patients
with a recent ACS.
We examined the primary composite (CV death, non-
fatal MI, stroke, or hospitalization for unstable angina),
CV composite (CV death, nonfatal MI, stroke, and hospi-
talization for heart failure (HF)), each of its components,
and all-cause mortality. Details of the trial design, entry
criteria, and the main results have been reported previ-
ously [18, 19].
For this post hoc analysis, all 6068 ELIXA participants
were included. Self-reported historical data on DR and
DN were collected at screening. Patients were asked to
answer “yes,” “no,” or “unknown” on the presence of DR
and/or DN. If DR was present, date of diagnosis was
recorded, as well as information on photocoagulation and
vitrectomy. However, these interventions were not analyzed
further due to a small number of events. Presence of DN
was deﬁned as a report of either sensory/motor or auto-
nomic neuropathy. Only “yes” responses were used to
deﬁne the exposure variables for all subsequent analyses.
Blood samples included in this analysis were done at
screening by a central laboratory. Duration of T2DM was
evaluated based on medical record review or self-report at
the screening visit.
2.2. Statistical Analysis. Baseline characteristics of patients
were stratiﬁed by the presence of DR and/or DN. Descriptive
data are presented as the mean± standard deviation for
normally distributed variables and as median (25–75th
percentile) for nonnormally distributed variables. Categor-
ical variables are expressed as proportions and were com-
pared by the chi-square test, while continuous variables
were compared using t-tests or Wilcoxon rank-sum tests, as
appropriate. Two proportional hazards regression models
were used to assess the association between DR, DN, and
recurrent CV events. Multivariable proportional hazards
models were used to assess the association between DR,
DN, and primary composite endpoint, CV composite end-
point, components, and all-cause mortality. Both DR and
DN were included in the ﬁrst model and adjusted for the
duration of T2DM. In the second model, demographic char-
acteristics and CV risk factors (age, sex, race, body mass
index (BMI), baseline HbA1c, smoking, history of hyperten-
sion (HT), heart rate, total cholesterol, low-density lipopro-
tein (LDL) cholesterol, and triglycerides) were added to the
previous model. Both models were adjusted for randomized
study treatment. Predictors of DR and DN were determined
from multivariable logistic regression model using forward
stepwise selection including all variables in Table 1. Two-
sided p values< 0.05 were considered signiﬁcant. No adjust-
ment was made for multiple comparisons. Analyses were
performed using the Stata version 13.1 (StataCorp., College
Station, TX, USA).
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Table 1: Characteristics of all patients at baseline according to the presence of retinopathy and/or neuropathy.
Characteristic All patients n = 6068 No retinopathy/
neuropathy n = 4705
Retinopathy and/
or neuropathy n = 1363 p value
Age (years) 60.3± 9.7 59.7± 9.7 62.3± 9.2 <0.001
Male sex (n (%)) 4207 (69.3) 3379 (71.8) 828 (60.7) <0.001
Body weight (kg) 84.9± 19.4 84.1± 18.9 87.6± 20.9 <0.001
Body mass index (kg/m2) 30.2± 5.7 29.9± 5.6 31.2± 6.0 <0.001
Duration of T2DM (years) 7.4 (2.8, 13.6) 6.0 (2.0, 11.7) 12.4 (7.0, 20.2) <0.001
Categories of T2DM duration (n (%)) <0.001
≤1 year 964 (15.9) 914 (19.4) 50 (3.7)
>1–≤5 years 1294 (21.3) 1130 (24.0) 164 (12.0)
>5–≤10 years 1359 (22.4) 1076 (22.9) 283 (20.8)
>10 years 2451 (40.4) 1585 (33.7) 866 (63.5)
Race (n (%)) <0.001
White 4576 (75.4) 3471 (73.8) 1105 (81.1)
Black 221 (3.6) 171 (3.6) 50 (3.7)
Asian 771 (12.7) 669 (14.2) 102 (7.5)
Other 500 (8.2) 394 (8.4) 106 (7.8)
Region (n (%)) <0.001
Africa/Near East 296 (4.9) 228 (4.8) 68 (5.0)
Asia Paciﬁc 703 (11.6) 615 (13.1) 88 (6.5)
Eastern Europe 1587 (26.2) 1115 (23.7) 472 (34.6)
North America 807 (13.3) 564 (12.0) 243 (17.8)
South and Central America 1944 (32.0) 1600 (34.0) 344 (25.2)
Western Europe 731 (12.0) 583 (12.4) 148 (10.9)
Smoking status (n (%)) <0.001
Current 709 (11.7) 579 (12.3) 130 (9.5)
Former 2746 (45.3) 2184 (46.4) 562 (41.2)
Never 2612 (43.1) 1941 (41.3) 671 (49.2)
Diastolic blood pressure (mmHg) 77± 10 77± 10 76.3± 10 <0.001
Systolic blood pressure (mmHg) 130± 17 129± 17 131± 17 <0.001
Heart rate (beats/min) 70± 10 70± 10 71± 10 0.027
Fasting plasma glucose (mg/dl) 148.3± 51.6 145.2± 49.1 159.3± 58.1 <0.001
Glycated hemoglobin (%) 7.7± 1.3 7.6± 1.3 8.0± 1.2 <0.001
Glycated hemoglobin (mmol/mol) 61± 14 60± 14 64± 13 <0.001
Total cholesterol (mg/dl) 153.5± 44.6 151.3± 43.5 161.1± 47.3 <0.001
HDL cholesterol (mg/dl) 42.9± 10.9 42.6± 10.6 44.1± 11.7 <0.001
LDL cholesterol (mg/dl) 78.5± 35.3 77.1± 34.7 83.4± 36.9 <0.001
Triglycerides (mg/dl) 137.2 (99.1, 195.6) 136.3 (100.0, 192.9) 141.6 (99.1, 208.0) 0.021
eGFR (ml/min/1.73m2) 76± 21 77± 21 71± 22 <0.001
Albuminuria (n (%)) <0.001
<30mg/g 4441 (74.3) 3579 (77.2) 862 (64.2)
≥30–<300mg/g 1148 (19.2) 819 (17.7) 329 (24.5)
≥300mg/g 389 (6.5) 237 (5.1) 152 (11.3)
Medical history at randomization (n (%))
Hypertension 4635 (76.4) 3463 (73.6) 1172 (86) <0.001
Heart failure 1358 (22.4) 923 (19.6) 435 (31.9) <0.001
Stroke 331 (5.5) 204 (4.3) 127 (9.3) <0.001
Peripheral arterial disease 393 (6.5) 227 (4.8) 166 (12.2) <0.001
Atrial ﬁbrillation 366 (6.0) 247 (5.2) 119 (8.7) <0.001
Percutaneous coronary intervention 4079 (67.2) 3263 (69.4) 816 (59.9) <0.001
Coronary artery bypass grafting 507 (8.4) 363 (7.7) 144 (10.6) <0.001
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3. Results
3.1. Baseline Characteristics. Demographic and clinical
characteristics of the 6068 patients are shown in Table 1.
In the whole population, the mean age was 60.3 years
and known T2DM duration was 7.4 years. However, the
reported duration of T2DM varied widely, with 15.9% of
participants having known T2DM for less than 1 year,
21.3% ≤5 years, 22.4% >1–≤5 years, and 40.4% longer
than10 years (Supplementary Figure 1). Of the whole pop-
ulation, 1363 (22.5%) reported DR and/or DN. DR was
reported in 651 (10.7%) patients, DN in 1060 (17.5%)
patients, and both in 348 (5.7%) patients (Figure 1). Of
651 who reported DR, 159 patients (24.4%) had prior pho-
tocoagulation, and 32 patients (4.9%) had vitrectomy.
Patients who had DR and/or DN were signiﬁcantly older
(mean 62.3 vs. 59.7 years) and had longer known duration of
T2DM (mean 12.4 vs. 6.0 years) than those with neither com-
plication. Smaller proportions of patients with DR and/or
DN reported shorter T2DM duration of <1 year (3.7% vs
19.4%) and ≤5 years (12.0% vs. 24.0%). The distribution of
T2DM duration in all patients, as well as in those with
and without retinopathy and/or neuropathy, is shown in
Figure 2. Participants with DR and/or DN also had higher
BMI, were also more likely to be nonsmokers, and had
signiﬁcantly higher glycated hemoglobin, fasting plasma
glucose, and total and LDL cholesterol. The subgroup with
DR and/or DN also had more evidence of renal disease
reﬂected as increased albumin-to-creatinine ratio in compar-
ison with those without DR and/or DN. Also, they were more
likely to have history of CV disease (HT, HF, stroke, periph-
eral arterial disease, and atrial ﬁbrillation). Finally, patients
with DR and/or DN used more frequently metformin and
insulin, while other glucose-lowering agents were similarly
distributed among groups (Table 1).
3.2. Retinopathy and/or Neuropathy and CV Outcomes. In
univariate analysis, DR was signiﬁcantly associated with
primary and CV composite endpoint, all-cause and CV
death, and all CV events except stroke (p = 0 068), while
DN was associated with primary and CV composite end-
point, all-cause death, and all nonfatal CV events, but not
CV death (p = 0 08, Table 2). When both DR and DN were
included in the same model, along with T2DM duration,
there were no independent associations of either with any
of the outcomes, while duration of T2DM remained highly
signiﬁcantly associated with all outcomes (Table 2). Further-
more, the addition of demographic characteristics and CV
risk factors to the previous model resulted in neither DR
nor DN being associated to any of the outcomes, but identi-
ﬁed duration of T2DM as an independent predictor of CV
events, beyond DR, DN, and CV risk factors (Table 2). There
were no signiﬁcant interactions between DR and DN in
adjusted and unadjusted models. It has previously been
reported that no signiﬁcant interactions were detected with
respect to prespeciﬁed patient subgroups for the ELIXA
Table 1: Continued.
Characteristic All patients n = 6068 No retinopathy/
neuropathy n = 4705
Retinopathy and/
or neuropathy n = 1363 p value
Qualifying ACS event (n (%)) <0.001
STEMI 2666 (44.0) 2187 (46.5) 479 (35.2)
NSTEMI 2348 (38.7) 1817 (38.6) 531 (39.0)
Unstable angina 1042 (17.2) 693 (14.7) 349 (25.6)
Missing 9 (0.1) 6 (0.1) 3 (0.2)
Antihyperglycemic therapy (n (%))
Metformin 4243 (69.9) 3367 (71.6) 876 (64.3) <0.001
Sulfonylureas 2266 (37.3) 1779 (37.8) 487 (35.7) 0.16
Insulin 2891 (47.6) 1948 (41.4) 943 (69.2) <0.001
Thiazolidinediones 128 (2.1) 92 (2.0) 36 (2.6) 0.12
Alpha-glucose inhibitor 181 (3.0) 150 (3.2) 31 (2.3) 0.08
Dipeptidyl peptidase 4 inhibitor 226 (3.7) 176 (3.7) 50 (3.7) 0.90
Other 485 (8.0) 384 (8.2) 101 (7.4) 0.37
Data is presented as means ± SD, median (25–75th percentile), or percentages. HDL: high-density lipoprotein; LDL: low-density lipoprotein; MI: myocardial
infarction; ACS: acute coronary syndrome; eGFR: estimated glomerular ﬁltration rate.
Retinopathy Neuropathy
5.0 % 5.7 % 11.6 %
Neither: 77.5 %
Retinopathy Neuropathy
Total population
Figure 1: Prevalence of retinopathy and/or neuropathy.
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primary composite outcome, which included T2DM dura-
tion< 10 vs. >10 years [19]. In addition, no statistically signif-
icant interactions were found with respect to DR, DN, or
duration of T2DM as a continuous variable.
3.3. Predictors of Retinopathy and/or Neuropathy. In both
univariate and multivariate analysis, the most signiﬁcant
predictors of both DR and DN were duration of T2DM
and insulin use (Table 3). The relationships between pres-
ence of DR and DN with duration of T2DM are shown in
Supplementary Figures 2a–b. In multivariate analysis,
other highly statistically signiﬁcant (p < 0 001) predictors of
DR were history of HF and stroke (Table 3) and of DN higher
weight were previous percutaneous coronary intervention
(PCI), total cholesterol, history of peripheral arterial disease,
and previous stroke (Table 3). These models were eﬀectively
able to discriminate between patients with and without DR
(area under the curve (AUC) 0.81) and DN (AUC 0.76).
4. Discussion
In this post hoc analysis of a large population selected for
having a recent ACS event, together with T2DM, less than
one-fourth of patients reported a history of DR, DN, or both.
This was a smaller proportion than found in other studies of
CV outcomes in T2DM, in which many patients had CV risk
factors but not necessarily a completed event. For example,
the prevalence of DR in the Trial to Reduce Cardiovascular
Events with Aranesp Therapy (TREAT) study—which also
relied on patient self-reports—was almost three times higher
in a more severely compromised patient cohort with T2DM,
chronic kidney disease, and anemia, but also twice as long
T2DM duration [20]. The widely varying duration of
T2DM in the ELIXA, and the inclusion of a large fraction
with very short duration of T2DM, allowed our analysis to
examine the relationships between duration of T2DM, pres-
ence of DR or DN, and risk of subsequent CV events.
The variability of previously reported associations
betweenDRand/orDNand subsequent CV events could stem
from variable T2DM duration and comorbidities of analyzed
patient cohorts. The positive association of DR and CV events
was observed in various patient cohorts [21–23]. In a recently
published study with a large cohort of T2DMpatients without
the history of CV diseases, the risk of developing CV death,
nonfatal MI, or stroke was about 40% higher in patients with
DR and DN [24]. In the meta-analysis including 11,505
patients, DR was associated with 1.7-fold increased risk for
CV events [25]. However, in the TREAT study, enrolling
4038patientswithT2DM,chronickidneydisease, andanemia,
DR was not independently associated with a higher risk of
renal or CV morbidity or death, possibly due to longer dura-
tion of T2DM and more comorbidities [20].
Our ﬁndings on DN are partially in accordance with pre-
viously published studies that revealed an association
between autonomic DN and CV events [26]. Other studies
have shown that DN was associated with a twofold risk
increase for peripheral vascular disease [27]. In our study,
we investigated the association of both DN and outcomes,
but not peripheral vascular disease. Therefore, our ﬁndings
on the large cohort of T2DM patients with recent ACS pro-
vide novel insight into the association between DN and
recurrent CV events. These ﬁndings indicate the importance
of the duration of T2DM as a traditional risk factor [28].
Consistent with prior reports, our analysis found that DR
and/or DN were associated at baseline with longer T2DM
duration, worse glycemic control, more insulin use, and his-
tory of prior manifest CV disease. Furthermore, both DR and
DN were associated with increased risk of recurrent CV
events, especially HF hospitalization. However, these associ-
ations were no longer statistically signiﬁcant after adjustment
for duration of T2DM, which remained a strong independent
predictor of CV events [20, 29, 30]. Thus, DR and DN as well
as duration of T2DM appear to be predictors of increased CV
risk but, unlike diabetic nephropathy, not themselves are
contributors to this risk.
While other relevant studies also adjusted clinical out-
comes for the duration of T2DM—among other demographic
characteristics andCVrisk factors—none of themadjusted for
only the known duration of the disease, whichmakes our ﬁnd-
ings unique. In a high-risk T2DM patient cohort used in the
Veterans Aﬀairs Diabetes Trial (VADT) (1791 subjects) [31],
the duration of T2DM was signiﬁcantly related to CV events.
However, to the best of our knowledge, no studies included
similar patient cohort, T2DM patients with recent ACS.
There are several possible explanations for the duration
of T2DM being a strong independent predictor of recurrent
CV events in our analysis. Longer duration of the disease
may have a direct eﬀect on progression of atherosclerotic
lesions, increasing the risk of a recurrent CV event. In addi-
tion, it might be associated with autonomic DN and reduced
heart rate variability, increasing the risk of CV death, which
was not the case in our cohort. A long-term increase in
.2
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0 20 40 60 0 20 40 60 0 302010 40 50
Fr
ac
tio
n
All patients
Duration of diabetes (years) Duration of diabetes (years) Duration of diabetes (years)
No retinopathy/neuropathy Retinopathy and/or neuropathy
.1
.05
.0
.2
.15
Fr
ac
tio
n
.1
.05
.0
.2
.15
Fr
ac
tio
n
.1
.05
.0
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oxidative stress in T2DM patients may cause increased risk of
CV death. Also, longer exposure to hyperglycemia may sim-
ply reﬂect greater exposure to other, perhaps unmeasured,
CV risk factors.
The major limitation of our study was the assessment
of DR and DN which was based on patients’ answers to
self-report questionnaires. Therefore, the prevalence of
both might have been underestimated. Such potential mis-
classiﬁcation bias might have potentially weakened our
results, and, therefore, the real association of DR and
DN with recurrent CV events could be stronger than pre-
sented in this analysis. Another important limitation is the
fact that T2DM duration was evaluated based on medical
record or self-report and could therefore be underesti-
mated, as patients often remain undiagnosed for many
years. Also, having in mind that the study cohort included
high-risk patients with T2DM and recent ACS, the results
may not be applicable to other populations such as those
without CV disease or with a less advanced stage of it.
In addition, the design of this study was cross-sectional
and therefore does not provide information on whether
or not DR and DN developed before or after the onset
of any CV disease antecedent to the qualifying ACS event.
Finally, our ﬁndings should be considered post hoc and
hypothesis-generating.
5. Conclusions
In a population with recent ACS together with T2DM, recur-
rent CV events, DR, and DNwere all strongly associated with
the T2DM duration. A history of either DR or DN was asso-
ciated with increased risk of recurrent CV events. As these
associations were eliminated by adjustment for the duration
of T2DM, which remained a strong independent predictor
of recurrent CV events, the link between DR and/or DN
and these events is not likely to be a causal one. However,
history of DR, DN, or both and longer duration of T2DM
could be considered clinical markers for high risk of recur-
rent CV events. It is important to point out that the presence
of both DN and DR is expected to positively correlate with
patients’ level of interaction with healthcare providers. Fur-
thermore, it is expected that their level of healthcare provider
interaction would correlate negatively with the frequency and
magnitude of adverse outcomes.
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Previous stroke 2.06 (1.51–2.82) 4.54 1.86 (1.42–2.45) 4.45
Diastolic blood pressure (per 10mmHg) — — 0.88 (0.82–0.95) 3.25
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ﬁltration rate; HDL: high-density lipoprotein; CABG: coronary artery bypass grafting; HbA1c: glycated hemoglobin; PAD: peripheral artery disease.
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